Efficacy News and Research

RSS

Immunopeptidomics offer new hope in cancer research

In this new omg OMx podcast episode, Bruker's Kate Stumpo speaks to Nicola Ternette on the incredible world of immunopeptidomics - the implications they could have for research and how they help us understand the immune system better.

From Bruker Daltonics 13 Dec 2023

Study highlights the necessity to refine the design of randomized cancer drugs trials in China

More than one-eighth of the randomized trials of cancer drugs seeking regulatory approval in China in recent years used inappropriate controls to test the effectiveness and safety of the drugs, according to a new study published December 12th in the open access journal PLOS Medicine by Professor Xiaodong Guan of Peking University, China, and colleagues.

12 Dec 2023

RBD-focused vaccines may offer broader protection against emerging COVID-19 variants

Published in The Lancet's eBioMedicine, 76 healthy adults from Melbourne, aged 18 to 64 who were previously vaccinated with licensed SARS-CoV-2 vaccines, were randomized to receive a fourth dose of a novel protein vaccine, mRNA vaccine or placebo.

12 Dec 2023

Nanoparticle vaccines can help fight zoonotic viral diseases

Announcing a new article publication for Zoonoses journal. Vaccines are the most promising tools for maintaining public health.

12 Dec 2023

Effectiveness of environmental interventions in managing autism

Researchers evaluate the health-related outcomes of nature-based interventions in children with autism.

12 Dec 2023

Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants

Five DNA vaccine candidates based on different SARS-CoV-2 strains.

12 Dec 2023

LA County invests big in free virtual mental health therapy for K-12 students

Los Angeles County public schools are rolling out an ambitious effort to offer free mental health services to their 1.3 million K-12 students, a key test of California Gov. Gavin Newsom's sweeping, $4.7 billion program to address a youth mental health crisis.

12 Dec 2023

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study.

From SolasCure 12 Dec 2023

New optimized vaccine approach targets Hepatitis C virus variability

A method to design vaccines for highly variable viruses like the hepatitis C virus.

12 Dec 2023

Gene therapy shows promise for arrhythmogenic cardiomyopathy

Researchers evaluated the effectiveness of adeno-associated virus (AAV)-mediated Plakophilin 2 (PKP2) delivery in treating arrhythmogenic cardiomyopathy (ACM).

12 Dec 2023

Synbiotic formula shows promise in reducing long COVID symptoms

Study finds that the synbiotic preparation SIM01 significantly reduces post-acute COVID-19 syndrome symptoms in patients, including fatigue, memory issues, and gastrointestinal distress, indicating its potential as a treatment for long COVID.

11 Dec 2023

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

Ketogenic diet proved to be effective at controlling polycystic kidney disease

It's official: The ketogenic diet proved to be effective at controlling polycystic kidney disease (PKD) in the first randomized controlled clinical trial of ketogenic metabolic therapy for PKD.

11 Dec 2023

Novel molecular link between vitamin B12 and multiple sclerosis revealed in astrocytes

For decades, scientists have noted an intriguing similarity between a deficiency in vitamin B12 – an essential nutrient that supports healthy development and functioning of the central nervous system (CNS) – and multiple sclerosis (MS), a chronic disease in which the body's immune system attacks the CNS and which can produce neurodegeneration.

11 Dec 2023

MIT scientists develop nanoparticles to reduce inflammation in the brain

Some Covid-19 vaccines safely and effectively used lipid nanoparticles (LNPs) to deliver messenger RNA to cells. A new MIT study shows that different nanoparticles could be used for a potential Alzheimer's disease (AD) therapy.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

From surviving to thriving: a framework for long-term success in people with HIV

NewsMedical spoke to Lisa Sterman, Global Executive Director, Global HIV Medical Affairs, Gilead Sciences, about the recently published LTS framework, recently highlighted at the opening ceremony of the 19th European AIDS Conference, which takes a person-centric approach to the HIV treatment journey.

From Gilead Sciences, Inc. 11 Dec 2023

Phase 2 trial data shows safety, tolerability and efficacy of imlifidase in GBS patients

Hansa Biopharma today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures.

11 Dec 2023

Efficacy News and Research

Immunopeptidomics offer new hope in cancer research

Study highlights the necessity to refine the design of randomized cancer drugs trials in China

RBD-focused vaccines may offer broader protection against emerging COVID-19 variants

Nanoparticle vaccines can help fight zoonotic viral diseases

Effectiveness of environmental interventions in managing autism

Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants

LA County invests big in free virtual mental health therapy for K-12 students

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

New optimized vaccine approach targets Hepatitis C virus variability

Gene therapy shows promise for arrhythmogenic cardiomyopathy

Synbiotic formula shows promise in reducing long COVID symptoms

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

Ketogenic diet proved to be effective at controlling polycystic kidney disease

Novel molecular link between vitamin B12 and multiple sclerosis revealed in astrocytes

MIT scientists develop nanoparticles to reduce inflammation in the brain

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

From surviving to thriving: a framework for long-term success in people with HIV

Phase 2 trial data shows safety, tolerability and efficacy of imlifidase in GBS patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News